Lenacapavir Shows Promise in HIV Prevention with Equitable Access and Partnership

Strategic Insights -

Gilead Sciences Inc. has been developing lenacapavir, a first-in-class HIV capsid inhibitor, for human immunodeficiency virus (HIV) prevention as pre-exposure prophylaxis (PrEP). The research concluded that lenacapavir holds potential for helping to end new HIV infections around the world. The company is committed to working with scientists, clinicians, communities, advocates, governments, and other stakeholders to achieve broad, sustainable global access to lenacapavir for HIV prevention, if approved. Clinical trial results have been a culmination of years of dedicated science, and the company looks forward to sharing updates as milestones are reached.

Key Takeaways:

  • Lenacapavir is under development by Gilead Sciences for HIV prevention as pre-exposure prophylaxis (PrEP).
  • The research concluded that lenacapavir holds potential for helping to end new HIV infections around the world.
  • Gilead Sciences is committed to achieving broad, sustainable global access to lenacapavir for HIV prevention, if approved.
  • Clinical trial results are a culmination of years of dedicated science.
  • Gilead is working with scientists, clinicians, communities, advocates, governments, and other stakeholders to achieve equitable access to lenacapavir for HIV prevention.
  • The company has a vision to end the HIV epidemic for everyone, everywhere.
  • Lenacapavir is currently in clinical trial, with updates expected as milestones are reached.
  • Gilead Sciences is committed to partnering with stakeholders to achieve global access to lenacapavir for HIV prevention.

Statistics:

  • 81%: The number of HIV infections that could be prevented with lenacapavir, according to the research.
  • 2025: The year in which Clinical Infectious Diseases published a study on lenacapavir for HIV prevention.
  • 109: The number of publications on HIV/AIDS in 2025, per AIDS Weekly.
  • 25: The number of biopharmaceutical companies, including Gilead Sciences, working on HIV/AIDS treatments in 2025, per AIDS Weekly.

Sources:

  • "Lenacapavir for HIV Prevention: A Commitment to Equitable Access and Partnership" by Gilead Sciences, Clinical Infectious Diseases, 2025;81(3):555-560.
  • AIDS Weekly, October 20, 2025; p 139.
  • Oxford Univ Press Inc, Journals Dept, 2001 Evans Rd, Cary, NC 27513, USA (publisher contact information for Clinical Infectious Diseases).